- Research article
- Open Access
- Open Peer Review
DNA-AP sites generation by Etoposide in whole blood cells
© Rojas et al; licensee BioMed Central Ltd. 2009
- Received: 28 May 2008
- Accepted: 16 November 2009
- Published: 16 November 2009
Etoposide is currently one of the most commonly used antitumor drugs. The mechanisms of action proposed for its antitumor activity are based mainly on its interaction with topoisomerase II. Etoposide effects in transformed cells have been described previously. The aim of the present study was to evaluate the genotoxic effects of this drug in non-transformed whole blood cells, such as occurs as collateral damage induced by some chemotherapies.
To determine etoposide genotoxicity, we employed Comet assay in two alkaline versions. To evaluate single strand breaks and delay repair sites we use pH 12.3 conditions and pH >13 to evidence alkali labile sites. With the purpose to quantified apurinic or apyrimidine (AP) sites we employed a specific restriction enzyme. Etoposide effects were determined on whole blood cells cultured in absence or presence of phytohemagglutinin (PHA) treated during 2 and 24 hours of cultured.
Alkaline (pH > 13) single cell gel electrophoresis (SCGE) assay experiments revealed etoposide-induced increases in DNA damage in phytohemaglutinine (PHA)-stimulated blood and non-stimulated blood cells. When the assay was performed at a less alkaline pH, 12.3, we observed DNA damage in PHA-stimulated blood cells consistent with the existence of alkali labile sites (ALSs). In an effort to elucidate the molecular events underlying this result, we applied exonuclease III (Exo III) in conjunction with a SCGE assay, enabling detection of DNA-AP sites along the genome. More DNA AP-sites were revealed by Exo III and ALSs were recognized by the SCGE assay only in the non-stimulated blood cells treated with etoposide.
Our results indicate that etoposide induces DNA damage specifically at DNA-AP sites in quiescent blood cells. This effect could be involved in the development of secondary malignancies associated with etoposide chemotherapy.
- Comet Assay
- Phenoxyl Radical
- Etoposide Treatment
- Alkali Labile Site
In the last decade, etoposide (also known as VP-16213) has been one of the most commonly used agents for treating a number of malignancies. Etoposide is a semi-synthetic derivative of epipodophyllotoxin derived from the plant Podophyllum peltatum [1–3]. Its primary intracellular target, topoisomerase II, alters DNA topology by passing an intact double helix through a transient double stranded break that it generates in a separate nucleic acid segment [4–6].
Topoisomerase II is required to resolve knots and tangles in the genetic material that are produced by physiological processes such as DNA recombination and replication [7–12]. In the absence of topoisomerase II, cells are unable to segregate daughter chromosomes and die of mitotic failure .
In contrast to most drugs that target specific enzymes, etoposide and other topoisomerase II-targeting anticancer agents act in a subtle manner. Rather than blocking the activity of this essential enzyme, etoposide kills cells by increasing the concentration of topoisomerase II-DNA cleavage complexes [7, 12, 14–16]. This action converts topoisomerase II into a potent cellular toxin that fragments the genome. Consequently, etoposide has been deemed a topoisomerase II poison, distinct from drugs that inhibit the overall catalytic activity of an enzyme [7, 12, 14–18]. It has been known for more than a decade that etoposide stabilizes topoisomerase II-associated DNA breaks, thereby abolishing the ability of the enzyme to ligate cleaved nucleic acid molecules [7, 12, 16, 19–21]. Specifically when etoposide interacts with topoisomerase IIα, it traps the enzyme in a covalently bound form with its DNA substrate [5, 22].
The topoisomeriase IIα-DNA complex is stabilized with the etoposide molecule by hydrogen bonds with the nucleic acid bases, and this stabilized complex thus prevents re-ligation of DNA by topoisomerase IIα [23, 24]. Both double-and single-strand breaks (SSBs) in DNA can be produced by etoposide.
The production of free radicals during etoposide metabolism has also been observed [25–27]. An orthoquinone metabolite of etoposide can be transformed into a hydroquinone . When oxidized, hydroquinones give rise to hydroxyl radicals, which may ultimately contribute to etoposide-associated SSBs in DNA . Although, the etoposide mechanism of action is well described in transformed cells, is important to know the effects generated in non-transformed whole blood cells as they are also exposed to the antineoplastic drug.
The Single Cell Gel Electrophoresis (SCGE) assay, also known as the comet assay, has been proposed as a sensitive, reliable and rapid method for detecting DNA SSBs, alkali labile sites (ALSs), and delayed repair sites (DRSs) in eukaryotic cells under extremely alkaline conditions (pH > 13) [29, 30]. Meanwhile, the SCGE assay reveals only SSBs and DRSs under less extreme alkali conditions (i.e. pH 12.3). Thus by comparing the SCGE results obtained at pH 12.3 to those obtained pH >13, it is possible to discriminate the accumulation of apurinic and apyrimidinic sites (AP sites), which produce ALSs, from other forms of DNA damage.
In this study, we used the alkaline SCGE assay at pH 12.3 and pH >13 in non-stimulated and PHA-stimulated human blood cells to assess the genotoxicity associated with etoposide-induced oxidative stress in non-transformed cells. We performed follow-up assays with exonuclease III enzyme (Exo III) to detect DNA-AP sites within the genome . The effect of co-treatment with an anti-oxidant, on etoposide genotoxicity was also examined. If etoposide treatment generates the production of reactive oxygen species, principally phenoxyl radicals, in non-stimulated whole blood cells, then exposure to an antioxidant should reduce the extent of DNA damage induced.
Chemical and reagents
Normal agarose, low melting point agarose (LMPA), ethidium bromide, Tris, Na2EDTA, DMSO (dimethyl sulfoxide), Phytohemaglutinin (PHA), Triton X-100, RPMI-1640 medium, and etoposide were obtained from Sigma Chemical Co. (St. Louis, MO), NaOH and NaCl were obtained from Merck (Mexico) and Baxter (Mexico), respectively. Exo III was obtained from Amersham Life Science (Piscataway, NJ, USA). Ascorbic acid (AA), also known as vitamin C, was obtained from ICN (Mexico).
Human blood cells and treatments
The protocol was approved by the Ethics committee of Instituto de Investigaciones Biomédicas at Universidad Nacional Autónoma de México. Whole blood samples were obtained by vein punction from normal healthy volunteers, who were non-smokers and not taking any medications. PHA-stimulated and non-stimulated whole blood cells were treated for 2 or 24 h with different etoposide concentrations (0, 2.07, 20.7 and 207 μM), in the presence of RPMI-1640 culture medium and maintained at 37°C under 5% CO2 conditions.
The etoposide concentrations were determined by assuming a body surface area of 1.63 m2 for the volunteers and calculating a dose equivalent to that used clinically for hematological malignancies. The calculated equivalent of the clinical dose was taken as the highest concentration applied in our study.
PHA-stimulated whole blood was first incubated for 6 h at 37°C under 5% CO2 conditions in 1 ml of RPMI-1640 culture medium with 71 μl of PHA, and then treated with etoposide as described above. To test the attenuation of etoposide AP-site generation in non-stimulated blood cells, the cultures were treated at the same time with AA (200 μM).
The dual cell-stain assay described by Hartman and Speit  was employed to determine the viability of the PHA-stimulated and the non stimulated whole blood cells after etoposide treatments. The analysis was performed with a fluorescence microscope (Olympus BX60); 4 fields and at least 400 cells per slide were scored. The results were expressed as percentage of cells alive relative to controls.
Single cell gel electrophoresis
The alkaline comet assay was performed essentially as described previously . Briefly, after the experimental treatment was applied, 20-μl samples of whole blood, both PHA-stimulated and non-stimulated, were dissolved in 0.5% LMPA, spread onto microscope slides precoated with 0.5% agarose, and covered with an additional 0.5% LMPA layer. The cells were then lysed in a high salt and detergent solution (2.5 M NaCl, 10 mM EDTA, 10 mM Tris pH 10, with fresh 10% DMSO and 1%Triton x-100), for at least 1 h at 4°C. Subsequently, the cells were placed in a horizontal electrophoresis chamber and exposed to an alkaline solution (300 mM NaOH, 1 mM Na2EDTA, pH >13) for 20 min to allow the DNA to unwind. For DNA electrophoresis, a 25-V electric current (300 mA, 0.8 V/cm) was applied for 20 min. All technical steps were conducted under very dim indirect light. After electrophoresis, the slides were gently removed and the alkaline pH was neutralized by application of 0.4 M Tris, pH 7.5. The slides were dehydrated in two steps with absolute ethanol for 5 min each. Ethidium bromide (75 μl of a 20 μg/ml solution) was added to each slide and a coverglass was placed on the gel.
We performed the comet assay at pH 12.3 as described in our previous report . The comet assay was also used in combination with Exo III as described by Gedik et al. . Briefly, cells were centrifuged at 200 × g for 3 min at 4°C, dispersed in 75 μl 1% low melting point agarose at 37°C, placed on a microscope slide an processed for the comet assay. For each sample, we divided the gel in two parts, the upper part of the gel was incubated with ExoIII and buffer and lower part with buffer alone. The parts were separated by a coverglass.
The measures of AP sites were obtained by subtraction of the mean comet assay score with enzyme buffer alone from that with ExoIII. DNA migration was analyzed on an Olympus BMX60 microscope with epifluorescence equipment (with a 515-560-nm excitation filter and a 590-nm barrier filter). DNA migration measurements (tail image length, in microns) were made with a scaled ocular. To identify the tail, the head of the comet was defined as the most brilliant circular region in the image. One hundred cells were scored for each treatment condition. All experiments were conducted in triplicate and scored in a double blind manner.
All statistical analyses were performed with STATISTICA software version 5 from STAT Soft Inc. USA (1996). The Mann-Whitney U test was used to determine DNA damage statistical differences between control cells and those treated with etoposide. Student's t test was used to compare cell viability, and Exo III recognition sites between control and etoposide-treated cells. For the evaluation of ALS, we used the Shapiro-Wilk "W" test which is used to probe normality . We compared each treatment with its particular control (2 h non-stimulated, 2 h stimulated, 24 h non-stimulated and 24 h stimulated) and with each etoposide concentration (0.0, 2.07, 20.7, 207.0). The results reported show that W test was not significant in all case (2 h non-stimulated, W = 0.867, P = 0.06148; 24 h non-stimulated, W = 0.9093, P = 0.20902); 2 h stimulated, W = 0.91198, P = 0.22618; 24 h stimulated, W = 0.93917, P = 0.48735, then the hypothesis that the respective distribution is normal was accepted. We performed a one way ANOVA test in order to detect if there was an effect of the etoposide concentration (0.0, 2.07, 20.7, 207.0) on the formation of akali-labile sites (ALS) in stimulated and non-stimulated cells at 2 h and 24 h.
Thereafter, a multiple comparison test (Tukey) was used to determine the significant differences between group means, particularly we analyzed if the control differed significantly with each etoposide concentration . The relationship between ALS index and net enzyme recognition sites was analyzed by Pearson's correlation.
Viability of non-stimulated and PHA-stimulated blood cells treated with etoposide as determined by dual-cell stain method.
2 h treatment non-stimulated blood cells
2 h treatment PHA-stimulated blood cells
100 ± 5.5
100 ± 5.6
95.5 ± 8.5
88.6 ± 3.9
99.2 ± 2.2
83.2 ± 8.2
91.1 ± 8.2
75.6 ± 7.6
24 h treatment non-stimulated blood cells
24 h treatment PHA-stimulated blood cells
100 ± 2.3
100 ± 3.9
100 ± 3.7
96.7 ± 3.4
100 ± 8.0
96.7 ± 3.4
93.8 ± 8.2
81.4 ± 9.9
Single cell gel electrophoresis
Alkali labile site (ALS) index
DNA AP-sites detection
Etoposide affects chromatin function by directly and physically interfering with topoisomerase IIα enzyme activity. Topoisomerase IIα is considered to be an important player in the maintenance of the DNA double helix, due to its capacity to regulate conformational changes in DNA, in normal processes such as replication, transcription or condensation and segregation of chromosomes [4–6].
Topoisomerase IIα activity fluctuates with the cell cycle; its levels elevate as the cells progress through the cycle toward mitosis [36–39]. Thus as structural maintenance of DNA is most challenged during DNA replication, it is expected that cycling cells would be the most susceptible to damage in the presence of etoposide. Because non-stimulated cells are not cycling, they have relatively low Topoisomerase II activity compared to PHA-stimulated whole blood cells, and thus would be expected to be relatively insensitive to DNA-damaging effects of etoposide.
The present findings of etoposide-induced DNA damage in non-stimulated cells differ from the findings of Olive and Banath  which indicated an absence of DNA damage induction by etoposide in non-cycling cells. This discrepancy is most likely due to inherent differences between the cells used in the experiments. Olive and Banath used colon carcinoma cells (WiDr), while we used human lymphocytes from healthy donors. Lymphocytes, such as those used here, are normally arrested in the G0 phase and non-transformed.
To asses the molecular processes involved in the etoposide treatment-induced breaks, we compared the non-stimulated whole blood cells genotoxicity data generated by the SCGE assay under both highly basic (= 12.3) and extremely basic (> 13) pH conditions and thus generated the ALS index values (see results section). This comparison enables the presence of ALSs to be deduced indirectly because the oxidative response capable of generating apurinic or apyrimidic sites (AP sites) is pH-dependent [41, 42]. The ALS index data indicated that ALSs, which can be generated by an oxidative stress [6, 33], constituted the primary form of DNA damage induced by etoposide in whole blood cells.
To asses whether oxidative stress was responsible for the DNA damage observed in the etoposide-treated non-stimulated cells, we used the SCGE assay in combination with Exo III, an enzyme that recognizes AP sites in DNA. The results corroborated the presence of DNA-AP sites in the genomes of the non-stimulated cells treated with etoposide. Moreover, when non-stimulated cells were exposed to etoposide in the presence of the antioxidant AA, less DNA damage was observed. Thus the ability of the antioxidant to protect the DNA suggests that phenoxyl radicals are the major radicals involved in the oxidative DNA-damage induced by etoposide, especially in non-stimulated cells [[27, 43], and ].
Interestingly, our results suggest that the molecular events by which DNA breaks are generated in PHA-stimulated and non-stimulated cells are quite different. The damage observed in the PHA-stimulated whole blood cells could be explained by the classical events ascribed to topoisomerase II poisons .
These have two principal components: DNA strand breaks due to the inhibition of topoisomerase II by etoposide and etoposide-quinone free radical effects [25, 45]. Tornov and colleagues  observed DNA damage in leukocytes evidenced by SCGE assay at pH 13, suggesting that etoposide might cause oxidative damage in leukocytes by a mechanism involving inhibition of the enzyme topoisomerase IIβ. Although the exact function of this enzyme has not been resolved, it is known that its concentration is generally independent of cell cycle and cell growth [[12, 37, 39], and ]. In addition, topoisomerase IIβ is expressed at a higher level than topoisomerase IIα in human peripheral blood cells . If the AP site damage observed in the present study was dependent upon an interaction with this enzyme, we should have also observed this kind of damage in PHA-stimulated whole blood cells. However our findings were not consistent with this prediction.
It is our view that the induction of damage at DNA-AP sites observed in non-stimulated whole blood cells herein was due to interaction of the drug metabolites with cellular targets beyond topoisomerase IIβ (which was not present at high levels), such as DNA and/or proteins. Interaction of the drug metabolites with these alternative targets can cause DNA damage by the generation of free radicals . Another possible explanation could be that DNA repair status in non-stimulated whole blood cells are less active than stimulated whole blood cells to remove this kind of DNA damage . Moreover, the reduced DNA damage in the presence of the antioxidant AA suggests that etoposide-hydroquinone phenoxyl radical is the responsible mediator of these effects [27, 49].
In summary, our data show that etoposide can produce differential forms of DNA damage in PHA-stimulated and non-stimulated blood cells. These results could have important implications for elucidating the mechanisms associated with the development of secondary malignancies (principally acute mielocitic leukemia) that are associated with the use of etoposide as an antineoplastic drug .
The authors thank Maria del Carmen López for her technical support. A professional scientific editor at Write Science Right was consulted during the preparation of this manuscript.
- van Maanen JMS, Retel J, de Vries J, Pinedo HM: Mechanisms of action of antitumor drug etoposide: a review. J Natl CancerInst. 1998, 80: 1526-1533.View ArticleGoogle Scholar
- Hainsworth JD, Greco FA: Etoposide: Twenty years later. Annals Oncol. 1995, 6: 325-341.Google Scholar
- Hande KR: Clinical Oncology Update, Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1998, 34 (10): 1514-1521.View ArticlePubMedGoogle Scholar
- Markovits J, Pommier Y, Kerrigan D, Covey JM, Tilchen EJ, Kohn KW: Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and in the cell cycle in NIH-3T3 fibroblasts and L1210 leukemia cells. Cancer Res. 1987, 47: 2050-2055.PubMedGoogle Scholar
- McPherson JP, Goldenberg GJ: Induction of apoptosis by deregulated expression of DNA topoisomerase IIL1. Can Res. 1998, 58: 4519-4524.Google Scholar
- Boos G, Stopper H: Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol Lett. 2000, 116: 7-16.View ArticlePubMedGoogle Scholar
- Burden DA, Osheroff N: Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. BiochimBiophys Acta. 1998, 1400: 139-154.Google Scholar
- Wang JC: DNA topoisomerases. Ann Rev Biochem. 1996, 65: 635-692.View ArticlePubMedGoogle Scholar
- Wang JC: Moving one DNA double helix through another by a type II DNA topoisomerase: The story of a simple molecular machine. Quart Rev Biophys. 1998, 31: 107-144.View ArticleGoogle Scholar
- Wang JC: Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002, 3: 430-440.View ArticlePubMedGoogle Scholar
- Nitiss JL: Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim Biophys Acta. 1998, 1400 (1-3): 63-81.View ArticlePubMedGoogle Scholar
- Fortune JM, Osheroff N: Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Prog Nucleic Acid Res Mol Biol. 2000, 64: 221-253.View ArticlePubMedGoogle Scholar
- Bromber KD, Burgin AB, Osheroff N: A two drug model for etoposide action against human topoisomerase II. J Biol Chem. 2002, 277: 31201-31206.View ArticleGoogle Scholar
- Pommier Y, Fesen MR, Goldwasser F: Cancer chemotherapy and Biotherapy: Principles and practice. Edited by: Chabner BA, Longo DL. 1996, Lippincott-Raven Publishers, Philadelphia, 435-461. 2Google Scholar
- Li TK, Liu LF: Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Phamacol Toxicol. 2001, 41: 53-77.View ArticleGoogle Scholar
- Wilstermann AM, Osheroff N: Base excision repair intermediates as topoisomerase II poisons. J Biol Chem. 2001, 276: 17727-17731.View ArticlePubMedGoogle Scholar
- Kreuzer KN, Cozarrelli NR: Escherichia coli mutants hermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. J Bacteriol. 1979, 140: 424-435.PubMedPubMed CentralGoogle Scholar
- Andoh T, Ishida R: Catalytic inhibitors of DNA topoisomerase II. Biochem Biophys Acta. 1998, 1400: 155-171.PubMedGoogle Scholar
- Osheroff N: Effect of antineoplastic agents on the DNA cleavage/religation reaction of the eukaryotic topoisomerase II: inhibition of DNA relegation by etoposide. Biochemestry. 1989, 28: 6157-6160.View ArticleGoogle Scholar
- Robinson MJ, Osheroff N: Effects of antineoplastic drugs on the poststrand-passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry. 1991, 30: 1807-1813.View ArticlePubMedGoogle Scholar
- Long BH: Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16). Seminars in Oncology. 1992, 19: 3-19.PubMedGoogle Scholar
- Kingma P, Osheroff N: The response of eukaryotic topoisomerases to DNA damage. Biochem Biophys Acta. 1998, 1400: 223-232.PubMedGoogle Scholar
- Wang JC: DNA topoisomerases. Annu Rev Biochem. 1985, 54: 665-697.View ArticlePubMedGoogle Scholar
- Pratt WB, Ruddon RW, Ensminger WD, Maybaum J: The anticancer drugs. 1996, Oxford University Press, New YorkGoogle Scholar
- van Maanem JM, Lafleur MV, Mans DR, Aker van den E, Ruiter C, Koostra PR, Pappie D, De Vries J, Retél J, Pinedo HM: Semiquinone formation from the catechol and ortho-quinone metabolites of the antitumor agent VP-16-213. Free Radic Res Commun. 1998, 4 (6): 371-84.View ArticleGoogle Scholar
- Kalyanaraman B, Nemec J, Sinha BK: Characterization of free radicals produced during oxidation of etoposide (VP-16) and its catechol and quinone derivatives. An ESR study. Biochemistry. 1989, 30: 4839-46.View ArticleGoogle Scholar
- Kagan VE, Yalowich JC, Day BW, Goldman R, Gantchev TG, Stoyanovsky DA: Ascorbate is the primary reductant of the phenoxyl radical of etoposide in the presence of thiols both in cell homogenates and in model systems. Biochemistry. 1994, 33: 9651-60.View ArticlePubMedGoogle Scholar
- Walles SAS, Zhou R, Liliemark E: DNA damage induced by etoposide; a comparison of two different methods for determination of strand breaks in DNA. Cancer Lett. 1996, 105: 153-159.View ArticlePubMedGoogle Scholar
- Rojas E, López MC, Valverde M: Single cell gel electrophoresis assay: methodology and applications. J Chromatography B. 1999, 722: 225-254.View ArticleGoogle Scholar
- Tice R, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki FC: Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen. 2000, 35: 206-221.View ArticlePubMedGoogle Scholar
- Rogers SG, Weiss B: Cloning of the exonuclease III gene of Escherichia coli. Gene. 1980, 11: 187-195.View ArticlePubMedGoogle Scholar
- Hartman A, Speit G: The contribution of cytotoxicity to DNA-effects in the single cell gel test (comet assay). ToxicolLett. 1997, 90 (2-3): 183-8.Google Scholar
- Rojas E, Valverde M, Kala SV, Kala G, Lieberman MW: Accumulation of DNA damage in the organs of mice deficient in γ-glutamyl transpeptidase. Mutat Res. 2000, 447: 305-316.View ArticlePubMedGoogle Scholar
- Gedik CM, Boyle SP, Wood SG, Vaughan NJ, Collins AR: Oxidative stress in humans: validation of biomarkers of DNA damage. Carcinogenesis. 2002, 23 (9): 1441-1446.View ArticlePubMedGoogle Scholar
- Cortés-Gutiérrez EI, Dávila-Rodríguez MI, López-Fernández C, Fernández JL, Gosálvez J: Alkali-labile sites in sperm cells from Sus and Ovis species. Int J Androl. 2008, 31 (3): 354-363.View ArticlePubMedGoogle Scholar
- Sandri MI, Hochhauser D, Ayton P, Camplejohn RC, Whitehouse R, Turley H, Gatter K, Hickson ID, Harris AL: Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. Br J Cancer. 1996, 73: 1518-1524.View ArticlePubMedPubMed CentralGoogle Scholar
- Herzog CE, Holmes KA, Tuschong LM, Ganapathi R, Zwelling LA: Absence of topoisomerase IIβ in an amsacrine-resistant human leukemia cell line with mutant topoisomerase II α1. Canc Res. 1998, 58: 5298-5300.Google Scholar
- Negri C, Chiesa R, Cerino A, Bestagno M, Sala C, Zini N, Maraldi NM, Astaldi RG: Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170 and 180 kDa isozymes. Exp Cell Res. 1992, 200: 452-459.View ArticlePubMedGoogle Scholar
- Stacey DW, Hitomi M, Chen G: Influence of cell cycle and oncogene activity upon topoisomerase IIα expression and drug toxicity. Mol Cell Biol. 2000, 20: 9127-9137.View ArticlePubMedPubMed CentralGoogle Scholar
- Olive PL, Banath JP: Growth fraction measured using the comet assay. Cell Prolif. 1992, 25: 447-457.View ArticlePubMedGoogle Scholar
- Fortini P, Raspaglio G, Falchi M, Dogliotti E: Analysis of DNA alkylation damage and repair in mammalian cells by the comet assay. Mutagenesis. 1996, 11: 169-75.View ArticlePubMedGoogle Scholar
- Horvátová E, Slamenová D, Hlinciková L, Kumar-Mandal T, Gábelová A, Collins AR: The nature and origin of DNA single-stranded breaks determined with the comet assay. Mut Res. 1998, 409: 163-171.View ArticleGoogle Scholar
- Ritov VB, Goldman R, Stoyanovsky DA, Menshikova EV, Kagan VE: Antioxidant paradoxes of phenolic compounds: peroxyl radical scavenger and lipid antioxidant, etoposide, inhibits sarcoplasmic reticulum Ca(2+)-ATPase via thiol oxidation by its phenoxyl radical. Arch Biochem Biophys. 1995, 321: 140-52.View ArticlePubMedGoogle Scholar
- Tyurina YY, Tyurin VA, Yalowich JC, Quinn PJ, Claycamp HG, Schnor NF, Pitt BR, Kagan VE: Phenoxyl radicals of etoposide (VP-16) can directly oxidize intracellular thiols: protective versus damaging effects of phenolic antioxidants. Toxicol Appl Pharmacol. 1995, 131: 277-88.View ArticlePubMedGoogle Scholar
- Gantchev TG, van Lier JE, Stoyanovsky DA, Yalowich JC, Kagan VE: Interactions of phenoxyl radical of antitumor drug, etoposide, with reductants in solution and in cell and nuclear homogenates: electron spins resonance and high-performance liquid chromatography. Methods in Enzymology. 1994, 234: 631-643.View ArticlePubMedGoogle Scholar
- Tornov VA, Konoplyannikov MA, Nikolskaya TA, Konstantinov EM: Apoptosis of unstimulated human lymphocytes and DNA strand breaks in topoisomerase II inhibitor etoposide (VP16). Biochemistry. 1999, 64: 345-352.Google Scholar
- Prosperi E, Negri C, Marchese G, Ricotti GC: Expression of the 170-kDa and 180-kDa isoforms of DNA topoisomerase II in resting and proliferating human lymphocytes. Cell Prolif. 1994, 27: 257-267.View ArticlePubMedGoogle Scholar
- Nouspikel T, Hanawalt PC: DNA repair in terminally differenciated cells. DNA repair. 2002, 1: 59-75.View ArticlePubMedGoogle Scholar
- Wenzel U, Nickel A, Kuntz S, Daniel H: Ascorbic acid suppresses drug-induced apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions. Carcinogenesis. 2004, 25 (5): 703-712.View ArticlePubMedGoogle Scholar
- Liu WM, Oackley PR, Joel SP: Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines. Leukemia. 2002, 16: 1705-1712.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/398/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.